India pharma news: Mankind Pharma’s ?511 crore ACTx deal, Dr Reddy’s US FDA observations, Aurobindo’s ADQUEY launch and Novo Nordisk’s sickle cell initiative.
Novo Nordisk’s 35 percent growth hormone drug price cut in India puts treatment affordability and access in focus.
AstraZeneca pays USD 40 million for AI drug targets, partnering with insitro to advance discovery for liver and heart diseases.
Vir Biotechnology and Gilead Sciences have signed a potential USD 1.9 billion deal to develop three dual-masked T-cell engager candidates for solid tumours.
More than nine lakh Delhi residents now have a health safety net through Ayushman Bharat, with expanded insurance cover, settled claims, and affordable medicines.
Vanda Pharmaceuticals has put its VQW-765 anxiety drug programme on hold after a Phase III trial failed to meet its primary endpoint.
A new experimental drug, ANB033, shows early promise in protecting people with celiac disease from gluten-induced intestinal damage and symptoms.
The Centre’s pharma push strengthens stent safety, expands clinical trial sites beyond metros and advances emergency care on Maharashtra highways.
Clinical trial site readiness gains focus as AstraZeneca and NIPER Raebareli partner to strengthen research infrastructure across 25 emerging Indian geographies.
The Biocon & Roche settlement clears a legal hurdle for Pebrilzo, highlighting how patent agreements shape biosimilar launch timelines across global markets.
.jpg)
, CDSCO.jpg "Fostering a Quality Culture in the Pharmaceutical Industry")
